Citius Pharmaceuticals, Inc. cash flow to debt ratio of -1.46K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Citius Pharmaceuticals, Inc.'s free cash flow has increased -5.85% from $-28.20M last year to $-26.55M, signaling increasing performance

Citius Pharmaceuticals, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Citius Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.01 today, signaling weakened financials

Citius Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Citius Pharmaceuticals, Inc.'s interest coverage ratio is -128.06, which means that the company struggles to meet interest obligations, signaling financial risk.

Citius Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Citius Pharmaceuticals, Inc.'s short-term liabilities of $44.91M exceed its short-term assets of $27.93M, signaling financial risk

Citius Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Citius Pharmaceuticals, Inc.'s return on equity of -67.42%, is lower than 15.00%, indicating bad performance

Citius Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Citius Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Citius Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Citius Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Citius Pharmaceuticals, Inc.'s yearly earnings has increased -4.36% since last year from $-39.14M to $-37.43M, signaling increasing performance

Citius Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -75.21% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Citius Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Citius Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Citius Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Citius Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Citius Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Citius Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Citius Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Citius Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Citius Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Citius Pharmaceuticals, Inc. has a price-to-book ratio of 0.22x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Citius Pharmaceuticals, Inc. has a price-to-sales ratio of 2.70x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue